Forbion

Mirae Asset Capital Life Science was formed in 2023 as a joint venture between Mirae Asset Capital and Mirae Asset Global Investments. It is the first and only U.S. affiliate for Mirae Asset dedicated to investment in Life Science. Near-Term ValueThe majority of our investments will be Series A/B and entering the clinic within a few years to generate real value with clinical proof of concept We believe companies at this stage maximize returns given the risk; we remain open to seed opportunities where there is a clear path to value and Series C opportunities if the valuation and resulting equity ownership support meaningful returns to our investors We aim to find the right mix between first-in-class and best-in-class assets with meaningful market share and evaluate both platform and single asset approaches Calculated RiskWe are modality agnostic when it comes to therapeutics and incredibly opportunistic with diagnostics Our interest in digital health involves using AI/ML tools (e.g. quantum computing, generative biology/chemistry) for drug discovery or protein engineering We co-invest with top-tier life science investors who we know and have worked with before and leverage our operational experience to find strong management teams with excellent track records relevant to the company they are building We aim to be active investors by securing board roles whenever possible; this is a role that is familiar to us and helps mitigate risk to our investors by helping to shape the course of our investments Innovative yet Validated ModalitiesWe have selected five core therapeutic sectors to focus our investments: Oncology, Immunology, CV/Metabolic, CNS/Ophthalmology, and Rare/Genetic Disease For each of the above sectors we have defined various focus areas defined by a unique combination of validation, unmet need, market potential, and acquisition/public market interest We seek to limit biological and technical risk and prioritize small molecule, antibody approaches (includes mAbs, bsAbs/TCEs, ADCs, radiotherapeutics), and nucleic acid therapeutics (siRNA, ASOs) across these sectors Rigorous EvaluationWe leverage the combined scientific background of our team and our affiliates in Asia (medicinal chemistry, pharmacology, structural biology) to perform rigorous evaluation of each investment We prepare a comprehensive diligence memo for each investment that includes a thorough evaluation of the science, pipeline, finance, management, board, investors, operations, regulatory, IP, clinical development, and potential return to our investors We conduct calls with relevant Key Opinion Leaders for every opportunity to ensure we have the most informed and updated views from the leading voices in the field

82VS is our affiliated venture studio that pairs Alloy’s platforms and services with a team of company creation experts to efficiently launch new asset-centric companies. Alloy works with exceptional founders, entrepreneurs- and executives-in-residence, and biotech and pharma partners to develop new medicines by efficiently leveraging the capabilities of the Alloy ecosystem at large. The 82VS name comes from the atomic number for lead, 82. To us, lead represents the most boring of metals that can form alloys, frequently used in low-cost solder to bring other metals together. This is because we seek to be behind the scenes and to fade into the background as we let our entrepreneurs and their companies take the credit for their great work. We Partner We partner with academics, entrepreneurs, target-rich companies, pharma, and VC. We lead with our drug discovery work, helping others advance targets of interest. We Build We build asset-focused companies while continuing to incorporate new modalities and drug discovery platforms accessible throughout the Alloy ecosystem. Alloy creates new platforms and services on demand to support individual new companies if needed. We Industrialize We industrialize repeatable company launch processes across legal, HR, finance, operations, and marketing to minimize startup time and allow scientists to focus on the science. Our People We come from pharma, biotech, academia, and venture capital backgrounds. Our EIRs can pursue their scientific ideas with full operational support and can repeatedly harness the 82VS infrastructure to create more value. We launch new companies and support strategic investments Collectively the companies supported out of 82VS are pursuing next generation innovative treatments for cancer, neurodegeneration, autoimmune disease, hereditary blindness, and more. Our investments in next-generation manufacturing companies help our ecosystem of partners advance more quickly to the clinic. We create, in-license, and co-develop pre-competitive enabling technology platforms that help the entire drug discovery community move faster. We value the work of inventors, ensuring your work lands with maximum impact. There is nothing more frustrating to a scientist or engineer than to see their life’s work trapped inside one company and only able to be accessed and improved by a single team. Alloy’s mission is to unlock the potential of pre-competitive technologies by taking a very long view of investing in platform development and helping our partners and venture studios utilize these technologies as aggressively as possible. Generally, platform technology continues to be improved over time and with greater use and engagement from the ecosystem. It’s exciting to think that the technologies we invent today will be supported, improved and available to our ecosystem today and long into the future. Alloy reinvests 100% of our revenue back into innovation and access to innovation while sharing the value with the innovators themselves.

As part of our investment approach, we developed a structured evaluation process, the “FemHealth Framework.” The first element (re)imagines women’s health as conditions appearing only in women, mostly in women, and differently in women. This concept from the FemHealth Framework (© 2019 FemHealth Ventures) was first published in 2019 and is increasingly thought of as a new lens through which to view women’s health. At FemHealth Ventures, we are excited about the increasing adoption of this broader definition of women’s health and the exciting new treatments it will engender. Only in Women Some conditions appear only in women. Examples include: endometriosis polycystic ovarian syndrome cervical cancer Mostly in Women Some conditions appear mostly in women. Examples include: breast cancer lupus multiple sclerosis Differently in Women Some conditions appear differently in women. Examples include: heart disease diabetes asthma Every cell has a sex A universe of possibilities is opened in women’s health when we start with the most basic building block: our cells. Each of the 30 trillion cells in a woman’s body has a different chromosomal makeup than a man. For example, a skin cell from a woman will have XX chromosomes, but a skin cell from a man will have XY chromosomes. This difference between women and men holds true throughout every single cell in the body. As a result, even the same disease can present differently in women versus men and require distinct treatment paradigms. Women’s health is more than “bikini medicine.” The term “bikini medicine” generally refers to conditions treated by obstetricians or gynecologists. We’ve (re)imagined women’s health as a broad spectrum of conditions that can impact the whole body, ranging from ovarian cancer, to autoimmune disease, to cardiovascular disease, and everything in between. A multitude of possibilities for innovation in women’s health exist. And we are here to help bring them to life.

Amgen Ventures has made >70 INVESTMENTS placing >$400M of the $625M Amgen has committed to support healthcare innovation and interconnectivity at all stages. Amgen Ventures offers us a unique conduit to identify and support key innovators in healthcare at early stages of translational sciences by providing investment capital and access to Amgen’s vast experience in developing leading drugs. AREAS OF INVESTMENTTHERAPEUTICS: Identify promising pipeline assets in Amgen’s therapeutic areas: oncology, immune- oncology, cardiovascular, inflammation, bone health, nephrology, metabolic disorders, and neuroscience. DRUG DISCOVERY & EMERGING TECHNOLOGIES: Improve the discovery process with new technologies including cell therapies, gene-editing and gene-therapies, regenerative medicine, and drug delivery. DIGITAL HEALTHCARE SERVICES, INFORMATION & ANALYTICS: Enhance Amgen medicines by improving real world outcomes and delivering greater value to healthcare systems, doctors, and patients.

We invest in the innovators behind the miracles of science who are passionate about improving human health. Sanofi Ventures serves as an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire. Our Approach As the corporate venture capital arm of Sanofi, we invest in top-tier biotech and digital health companies that focus on helping patients and transforming the practice of medicine. We invest across all stages of the private company lifecycle, from Seed to Series B and beyond, while leading financings, serving on boards, and taking pride in working alongside portfolio companies to drive long-term value through future financings and IPO. How We Work Think of us like institutional venture capitalists with an added bonus: in addition to our investment, we aim to offer our portfolio companies select access to Sanofi’s expertise and capabilities in science, preclinical and clinical development, regulatory, data analytics, manufacturing, market access, and commercialization. Our goal is to foster strong relationships over time so when our portfolio company is ready to consider a partnership or acquisition, our colleagues on the BD and M&A teams can be a first and last call. We move quickly, we don’t believe in drawn-out processes, and we always aim to provide thoughtful feedback. Our Investment Focus We invest in early-stage biotech and digital health companies of strategic interest to Sanofi. We seek to accelerate all strategic focus while reaching into novel and emerging areas of science and technology. Here are some of the areas that we currently are thinking about: Rare diseases Immunology and inflammation Oncology Cell and gene therapy Vaccines Digital health and data science We can't do it alone - we would love to hear how we can team up to improve human health for people everywhere!

Aditum Bio brings together unmatched scientific and domain expertise with agile operational capabilities. Our unique investment and operating model enables rapid company formation, planning, and execution to advance novel drug candidates into the clinic and speed their delivery to the patients in need. PROVEN INDUSTRY LEADERSHIP AND SCIENTIFIC EXPERTISE Launched by former Novartis CEO, Joe Jimenez, and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, the experience of our founding executive team provides Aditum Bio with a unique lens for identifying and selecting innovative drug candidates with unrecognized potential. BETTER OUTCOMES FOR PATIENTS. FASTER RETURNS FOR INVESTORS. By singularly focusing on the translation phase of drug development, Aditum Bio efficiently identifies and develops potentially first- and best-in-class therapies for a broad array of diseases – empowering our ability to reach more patients and creating faster return for its capital investments. OUR VALUES: ROOTED IN SCIENCE, INSPIRED BY PATIENTS Aditum Bio is a new breed of biotech investment firm that is driven to translate science into the new medicines that make a meaningful difference in the lives of patients. We are a dedicated and ambitious team that is tightly aligned by a set of core values that underscore the important work we do. WE ARE PATIENT CENTRIC We have a passion to help patients, and this drives our decision making. We believe that our role is to develop therapies for patients with disorders currently neglected but which are scientifically tractable. WE ARE COLLABORATIVE We believe that we can accomplish more as a team than we can as individuals. We are respectful of each other and listen to understand. We enjoy fierce debate among ourselves to get to the right decision, but in a way that is respectful and appreciative. We pick our colleagues up when they are down. WE ARE CURIOUS We are a collection of people with high learning agility, and believe that no matter what age, we all have much to learn. We change our opinion without hesitation or embarrassment when new facts arise. We seek out the best experts in the world as advisors. WE ARE COURAGEOUS We define the single most important question to a new therapy’s success, then have the courage to answer it. We have a high emotional need to take on challenges and deliver results. We believe it is better to act on 80% of an answer than wait for the remaining 20%. We have the courage to stand up for our beliefs, but the humbleness to consider other viewpoints. FULLFILLING THE PROMISE OF SCIENCE Genetic, genomic and artificial intelligence have led to the discovery of new drug targets and therapeutic modalities; however, many drug candidates fail to be developed due to strategic decisions and high clinical trial expense. Aditum Bio stands apart in the biotech venture capital arena through our differentiated approach for identifying promising, clinic-ready therapies that offer value for underserved patient populations, in areas such as obesity, depression, substance abuse, renal disease, and infectious diseases. ACCELERATING BIOTECH COMPANY FORMATION Harnessing our experienced in-house R&D domain experts as the foundation of our agile operating model, Aditum Bio is able to accelerate the formation and ramp-up of its portfolio companies. We augment each company's newly-established, dedicated leadership team with medical and scientific experts. Operating under the Aditum Bio umbrella in a lean and efficient management structure, portfolio companies are empowered to rapidly progress newly-acquired drug candidates into Phase 2 clinical trials. LEVERAGING TECHNOLOGY FOR EFFICIENT TRIAL EXECUTION Aditum Bio’s strategic advantage extends to its proven acumen for using an array of powerful technologies and digital tools throughout its portfolio companies to support clinical trial execution at the highest level of efficiency. Through our in-house technology capabilities and our extensive partnerships with leading solutions providers, we enable therapies to advance more quickly and at lower cost than in traditional R&D models.